Noninvasive Proton Beam Therapy Cuts Dangerous Heart

What Is Proton Beam Therapy for Heart Rhythm Disorders?

Ventricular tachycardia (VT) is a rapid, abnormal heart rhythm originating in the lower chambers of the heart and can lead to sudden cardiac death if untreated. Standard treatments include implantable cardioverter-defibrillators (ICDs), antiarrhythmic medications, and catheter ablation, in which a thin tube is threaded into the heart to burn or freeze the tissue generating the abnormal signals. However, catheter ablation can fail in patients with deep-seated scar tissue or those too frail for invasive procedures.

Proton beam therapy delivers a focused beam of charged particles that deposit their energy at a precise depth, sparing surrounding tissue. Originally developed for hard-to-reach tumors, researchers at Mayo Clinic have now adapted the technology to target the small regions of heart muscle responsible for VT. Unlike photon-based stereotactic radioablation, protons offer a sharper dose fall-off, potentially reducing radiation exposure to healthy heart tissue, lungs, and the esophagus.

How Effective Was the Mayo Clinic Trial?

According to the Mayo Clinic research team, participants enrolled in this early feasibility study had refractory VT — meaning they had failed multiple prior therapies and continued to experience life-threatening arrhythmias despite ICDs and medications. Each patient received a single, carefully planned proton beam treatment delivered while awake, with no incisions, anesthesia, or catheters required. The procedure took less than an hour.

The reported reduction of nearly 80% in VT episodes is consistent with earlier work using photon-based stereotactic body radiation therapy (SBRT), pioneered at Washington University in St. Louis. By switching to protons, investigators hope to maintain or improve efficacy while reducing late radiation toxicity to surrounding organs. Larger trials will be needed to confirm long-term safety, durability of effect, and whether proton therapy should become standard for select patients with refractory VT.

Who Could Benefit from This Treatment?

The strongest candidates are patients with prior heart attacks or cardiomyopathy who have developed scar-related VT and continue to experience frequent ICD shocks. ICD shocks, while life-saving, are painful and associated with worsened quality of life and increased mortality. Many of these patients are too sick for repeat catheter ablation, which requires general anesthesia and prolonged time in a fluoroscopy suite.

Cardiac radioablation — whether with photons or protons — represents a paradigm shift in electrophysiology, where treatment can be delivered in a radiation oncology suite rather than a catheterization lab. Specialists from cardiology, radiation oncology, and medical physics must collaborate closely to map the arrhythmia substrate using cardiac imaging and electroanatomic data, then translate that map into a precise radiation plan.